300204 Stock Overview
Staidson (Beijing) BioPharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.41 |
| 52 Week High | CN¥10.38 |
| 52 Week Low | CN¥5.41 |
| Beta | 0.47 |
| 1 Month Change | -11.79% |
| 3 Month Change | -6.08% |
| 1 Year Change | -26.71% |
| 3 Year Change | -57.66% |
| 5 Year Change | -34.60% |
| Change since IPO | 4.81% |
Recent News & Updates
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected
Oct 08
Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%
Aug 03Recent updates
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected
Oct 08Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%
Aug 03There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump
Aug 02What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You
Mar 18Shareholder Returns
| 300204 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.9% | -0.8% | 1.0% |
| 1Y | -26.7% | -22.3% | 8.2% |
Return vs Industry: 300204 underperformed the CN Biotechs industry which returned -22.3% over the past year.
Return vs Market: 300204 underperformed the CN Market which returned 8.2% over the past year.
Price Volatility
| 300204 volatility | |
|---|---|
| 300204 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 300204 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300204's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 547 | Wang Chao | www.staidson.com |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Troponium Chloride Capsules, Gliclazide extended-release tablets, Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C. Staidson (Beijing) BioPharmaceuticals Co., Ltd.
Staidson (Beijing) BioPharmaceuticals Co., Ltd. Fundamentals Summary
| 300204 fundamental statistics | |
|---|---|
| Market cap | CN¥3.62b |
| Earnings (TTM) | -CN¥223.29m |
| Revenue (TTM) | CN¥350.71m |
10.1x
P/S Ratio-15.9x
P/E RatioIs 300204 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300204 income statement (TTM) | |
|---|---|
| Revenue | CN¥350.71m |
| Cost of Revenue | CN¥71.97m |
| Gross Profit | CN¥278.74m |
| Other Expenses | CN¥502.02m |
| Earnings | -CN¥223.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 79.48% |
| Net Profit Margin | -63.67% |
| Debt/Equity Ratio | 0% |
How did 300204 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 17:02 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Zhang | AJ Securities Co., Ltd |
| YANG QIAO | Changjiang Securities Co. LTD. |
| Ling Bo Tu | China Minzu Securities |